Children with cystic fibrosis (CF) have an increased risk of morbidity and higher case fatality during the influenza pandemic compared to patients with other chronic respiratory diseases or healthy controls.
The Food and Drug Administration (FDA) has granted Orphan Drug designation to Lynovex (NM001; NovaBiotics) for the treatment of cystic fibrosis (CF).
In the United States, children born in 2010 with cystic fibrosis (CF) are projected to live longer than those born earlier.
Fresenius Kabi announced the launch of Acetylcysteine Solution, 10%.
Vertex announced results from two Phase 3 studies of lumacaftor in combination with ivacaftor in patients with cystic fibrosis (CF) who have two copies of F508del mutation in the CFTR gene.
Fresenius Kabi USA announced its launch of Acetylcysteine Solution 20% in 4mL vials for inhalation or oral administration.
The FDA has approved a sNDA for Kalydeco (ivacaftor; Vertex) for use in patients with cystic fibrosis (CF) ages >6 years old who have 1 of 8 additional mutations in the CF transmembrane conductance regulator (CFTR) gene.
Ben Venue Laboratories announced a nationwide recall of Roxane’s Acetylcysteine Solution 10%.
Fresenius Kabi USA has announced the launch of Acetylcysteine Solution 20% in a 10mL vial for inhalation or oral administration.
There is currently a lack of evidence showing the benefit of certain therapies to clear mucus in the lungs when performed routinely in hospitals, according to the American Association for Respiratory Care (AARC).
